The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older ...

Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to the career path of his predecessor, Anat Ashkenazi, who also spent two ...